Restenosis: Emerging molecular targets: Going beyond drug-eluting stents

Xiaoguang Chen, Kenichi Fujise

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Within a few decades atherosclerosis and coronary artery diseases will be a global disease. Percutaneous coronary intervention (PCI), one of the most important treatment strategies for CAD, will thus be utilized much more extensively. Restenosis will remain the most common and feared complication of PCI, even with the widespread use of drug-eluting stents (DES). Two distinct processes contribute to restenosis: The increased cellular mass in the intima (neointimal proliferation) and the negative remodeling of the artery. A new molecular approach will lead to the discovery of effective antirestenosis molecules that block both neointimal proliferation and negative remodeling. Vascular smooth muscle cells will be the most promising cell type to be targeted.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalDrug Discovery Today: Disease Mechanisms
Volume2
Issue number1
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Drug-Eluting Stents
Percutaneous Coronary Intervention
Vascular Smooth Muscle
Smooth Muscle Myocytes
Coronary Artery Disease
Atherosclerosis
Arteries

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

Restenosis : Emerging molecular targets: Going beyond drug-eluting stents. / Chen, Xiaoguang; Fujise, Kenichi.

In: Drug Discovery Today: Disease Mechanisms, Vol. 2, No. 1, 2005, p. 1-9.

Research output: Contribution to journalArticle

@article{09a0463c2a5949e9b5fe03c27456a31f,
title = "Restenosis: Emerging molecular targets: Going beyond drug-eluting stents",
abstract = "Within a few decades atherosclerosis and coronary artery diseases will be a global disease. Percutaneous coronary intervention (PCI), one of the most important treatment strategies for CAD, will thus be utilized much more extensively. Restenosis will remain the most common and feared complication of PCI, even with the widespread use of drug-eluting stents (DES). Two distinct processes contribute to restenosis: The increased cellular mass in the intima (neointimal proliferation) and the negative remodeling of the artery. A new molecular approach will lead to the discovery of effective antirestenosis molecules that block both neointimal proliferation and negative remodeling. Vascular smooth muscle cells will be the most promising cell type to be targeted.",
author = "Xiaoguang Chen and Kenichi Fujise",
year = "2005",
doi = "10.1016/j.ddmec.2005.05.025",
language = "English (US)",
volume = "2",
pages = "1--9",
journal = "Drug Discovery Today: Disease Mechanisms",
issn = "1740-6765",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Restenosis

T2 - Emerging molecular targets: Going beyond drug-eluting stents

AU - Chen, Xiaoguang

AU - Fujise, Kenichi

PY - 2005

Y1 - 2005

N2 - Within a few decades atherosclerosis and coronary artery diseases will be a global disease. Percutaneous coronary intervention (PCI), one of the most important treatment strategies for CAD, will thus be utilized much more extensively. Restenosis will remain the most common and feared complication of PCI, even with the widespread use of drug-eluting stents (DES). Two distinct processes contribute to restenosis: The increased cellular mass in the intima (neointimal proliferation) and the negative remodeling of the artery. A new molecular approach will lead to the discovery of effective antirestenosis molecules that block both neointimal proliferation and negative remodeling. Vascular smooth muscle cells will be the most promising cell type to be targeted.

AB - Within a few decades atherosclerosis and coronary artery diseases will be a global disease. Percutaneous coronary intervention (PCI), one of the most important treatment strategies for CAD, will thus be utilized much more extensively. Restenosis will remain the most common and feared complication of PCI, even with the widespread use of drug-eluting stents (DES). Two distinct processes contribute to restenosis: The increased cellular mass in the intima (neointimal proliferation) and the negative remodeling of the artery. A new molecular approach will lead to the discovery of effective antirestenosis molecules that block both neointimal proliferation and negative remodeling. Vascular smooth muscle cells will be the most promising cell type to be targeted.

UR - http://www.scopus.com/inward/record.url?scp=33645084784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645084784&partnerID=8YFLogxK

U2 - 10.1016/j.ddmec.2005.05.025

DO - 10.1016/j.ddmec.2005.05.025

M3 - Article

AN - SCOPUS:33645084784

VL - 2

SP - 1

EP - 9

JO - Drug Discovery Today: Disease Mechanisms

JF - Drug Discovery Today: Disease Mechanisms

SN - 1740-6765

IS - 1

ER -